Press Releases 2020 / 2021

May 11, 2021

 

Oculis Announces Positive Data from Two Proof-of-Concept Phase 2 Trials with OCS-02, Presented at ARVO 2021

May 04, 2021

 

Oculis Announces an Oversubscribed US$57 million Series C Financing

November 24, 2020

 

Oculis to present recent progress in its portfolio at upcoming Investor Conferences

October 22, 2020

 

Oculis appoints David Jacobs, M.D. as Chief Development Officer

October 05, 2020

 

Oculis announces presentation of OCS-01 Phase 2 DME study at EURETINA 2020

September 22, 2020

 

Oculis to present recent milestones at key biotech and ophthalmology conferences

September 22, 2020

 

Oculis recognized as one of the Top 100 Swiss Startups and ranked in Top 10 Biotech

September 1, 2020

 

Oculis establishes presence in U.S. and appoints Sylvia Cheung as Chief Financial Officer 

August 10, 2020

 

Oculis to present recent phase 2 clinical trials results at the upcoming 2020 Summer Private Company Showcase

July 30, 2020

 

Oculis to present recent progress in its portfolio at the LifeSCi Partners Private Company Virtual Summer Symposium

July 27, 2020

 

Oculis announces successful end-of-phase 2 meeting with the FDA for OCS-01

June 23, 2020

 

Oculis to discuss recent positive clinical milestones achieved at upcoming virtual European Biotech Investor Day 2020

May 18, 2020

 

Oculis reports positive phase 2 results from SKYGGN trial with OCS-01

May 07, 2020

 

Oculis announces upcoming presentation of SKYGGN phase 2 data of OCS-01 in post-cataract surgery at ASCRS

April 21, 2020

 

Oculis appoints Dr. Frédéric Pilotaz as VP of Tehcnology & Pharmaceutical Sciences

March 03, 2020

 

Oculis appoints Marcia de Souza Lima, M.D., as Chief Medical Officer

February 10, 2020

 

Oculis announces positive phase 2 results with OCS-01: Potentially the first topical therapeutic for DME

January 22, 2020

 

Oculis announces upcoming presentation of phase 2 data of OCS-01 in DME